Abstract. The roles of Src homology domain 2-containing protein tyrosine phosphatase 2 (SHP-2) and its signaling in atherosclerosis have not been explored. Therefore, we investigated the roles of SHP-2 in the movement of rat aortic smooth muscle cells (RASMCs) and in the neointima formation of the carotid artery. Platelet-derived growth factor (PDGF)-BB (1 − 20 ng/ml) increased the activity and phosphorylation of SHP-2 and migration in RASMCs and these were suppressed by SHP-2 inhibitor NSC-87877 (30 μM) and small interfering RNA of SHP-2. PDGF-BB increased the phosphorylations of spleen tyrosine kinase (Syk) and p38 mitogen-activated protein kinase (MAPK), which were recovered by inhibition of SHP-2. Moreover, PDGF-BB increased the levels of reactive oxygen species (ROS) and ROS inhibitors decreased PDGF-BB-increased migration. Treatment of RASMCs with H 2 O 2 (100 μM) increased cell migration and SHP-2 phosphorylation and also enhanced the phosphorylation levels of Syk and p38 MAPK. Oral administration of NSC-87877 (10 mg/kg) significantly suppressed neointima formation in a rat model of carotid artery injury. These results suggest that the activity of SHP-2 is controlled by ROS and is positively involved in the regulation of PDGF-BB-induced RASMC migration and neointima formation.
Introduction
Platelet-derived growth factor (PDGF) is a potent growth factor that stimulates vascular smooth muscle cell (VSMC) migration. This is an essential process for the development of intimal thickening during vascular tissue remodeling in circulatory disorders including atherosclerosis (1) . PDGF stimulates the autophosphorylation and activation of PDGF-receptor tyrosine kinase (PDGF-R), causing the phosphorylation of tyrosine on a number of Src homology 2 (SH2) domain-containing intracellular signaling proteins, such as SH2-containing protein tyrosine phosphatase 2 (SHP-2) (2). These initiate various PDGF-induced signaling processes including the activation of mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinases 1/2, p38 MAPK, and stress-activated protein kinase / c-Jun Nterminal kinase (3, 4) .
Reactive oxygen species (ROS) represent a class of oxygen-derived molecules that act as physiological or pathophysiological signaling molecules in various vascular functions and diseases (5, 6) . ROS, such as superoxide anion (O 2 − ) and hydrogen peroxide (H 2 O 2 ), can be generated through the activation of NADPH oxidase (NOX), which is mediated by PDGF stimulation (7, 8) . ROS are also involved in PDGF-stimulated migration in VSMCs (9) . Moreover, gene transfer to neointima of redox factor-1, an antioxidant protein, attenuated the formation of vascular neointima (1) . We also confirmed recently that spleen tyrosine kinase (Syk) and p38 MAPK participate in the regulation of PDGF-induced migration in rat aortic smooth muscle cells (RASMCs) (10) .
Protein tyrosine phosphatases (PTPs) are important targets of ROS (5) . They regulate signal transduction in receptors containing protein tyrosine kinase and participate in determining the level of tyrosine phosphorylation (11) . SHP-2 is one of the cytoplasmic PTPs expressed in several cell types including VSMCs (12 − 14) . SHP-2 is believed to be a target of protein tyrosine kinases. It can bind directly to PDGF-R (15, 16) and is thought to contribute to the proximal signaling events of PDGF-R (17, 18) . Although most PTPs increase the dephosphorylation of proteins and act as negative regulators in response to extracellular stimuli, SHP-2 is believed to be a positive mediator of the PDGF signal (19, 20) . SHP-2 is involved in several signaling cascades, including the Src-family kinase (SFK) and MAPK pathways, which mediate a variety of cell functions including migration, proliferation, and growth (21, 22) . SHP-2 acts as a mediator of the regulation of motility in various cells such as cancer cells and fibroblasts (23, 24) . It has been suggested that increased SHP-2 expression may accelerate aortic atherosclerosis via the increasing VSMC proliferation (25) . However, the contribution of SHP-2 and its signal transduction in response to PDGF in vascular cell migration has not been investigated. Therefore, in this study we investigated the role of SHP-2 and clarified the relationship between its activity and ROS in the PDGF-BB-induced migration and signaling pathways in RASMCs and in neointima formation following carotid artery injury.
Materials and Methods
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and approved by the Animal Subjects Committee of Konkuk University School of Medicine. All experiments were performed in accordance with the institutional guidelines of Konkuk University.
Materials
Bovine serum albumin (BSA), elastase, heparin, trichloroacetic acid (TCA), and H 2 O 2 were purchased from Sigma (St. Louis, MO, USA). Dulbecco's modified eagle medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin, phosphate-buffered saline (PBS), and trypsin-ethylenediamine tetraacetic acid (EDTA), and other cell culture materials were obtained from Hyclone (Logan, UT, USA) or Invitrogen (Carlsbad, CA, USA). NSC-87877 [8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid] was purchased from Acros Organic (Morris Plains, NJ, USA). PDGF-BB (R&D Systems, Minneapolis, MN, USA), type I collagen from rat tail tendon (BD Bioscience, Franklin Lakes, NJ, USA), and collagenase (Wako, Richmond, VA, USA) were used. The following antibodies were used in this study: anti-SHP-2, anti-phospho-SHP-2 that recognizes the phosphorylated SHP-2 at Tyr-542, antip38 MAPK, and anti-phospho-p38 MAPK (Cell Signaling, Beverly, MA, USA); anti-Syk (Abcam, Cambridge, UK); anti-phospho-tyrosine(4G10) (Upstate, Lake Placid, NY); and anti-β-actin (Sigma) antibodies. Other chemicals and cell culture materials were obtained from Sigma, Hyclone, or Invitrogen.
Cell culture
RASMCs were isolated enzymatically from 6-weekold male Sprague Dawley (SD) rats (160 -180 g, n = 8) by collagenase and elastase treatment, and the cells were used for experiments in passages 4 -8. Cells were cultured in DMEM containing 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, and 200 mM glutamine. For all experiments, RASMCs were grown to 70% -80% confluence and starved in DMEM without FBS for 24 h. Cells were grown at 37°C under a humidified 95% to 5% (vol/vol) mixture of air and CO 2 .
Immunoprecipitation and immunoblotting
Protein phosphorylation was measured by immunoprecipitation and immunoblotting with antibodies as reported previously (1, 10) . After treatment with stimulants, cells (3 × 10 5 ) were lysed with cold extraction buffer (20 mM HEPES, pH 7.5, 1% Nonidet P-40, 150 mM NaCl, 10% glycerol, 10 mM NaF, 1 mM Na 3 VO 4 , 2.5 mM 4-nitrophenylphosphate, 0.5 mM PMSF, and 1 tablet of complete proteinase inhibitor cocktail, PIC). Lysates containing 500 μg of proteins were incubated for 5 h with 4 μg/ml of antibodies at room temperature. The immunocomplex was then precipitated overnight using protein A-agarose beads (Sigma) at 4°C. The beads were washed with PBS containing Tween-20 and were re-suspended in the SDS sample buffer containing 40 mM Tris-HCl (pH 6.8), 8 mM EGTA, 4% 2-mercaptoethanol, 40% glycerol, 0.01% bromophenol blue, and 4% SDS and then boiled for 7 min. Proteins (20 -30 μg per lane) were separated on a 12% SDS-polyacrylamide gel and then transferred electrophoretically to a PVDF membrane (Millipore, Billerica, MA, USA). The membrane was blocked for 2 h at room temperature with PBS containing 0.05% Tween 20 and 5% fat-free dried milk. The membrane was incubated with antibodies diluted 1:1000 -5000 overnight at 4°C. Immune complexes were detected with horseradish peroxidase-conjugated antibodies diluted 1:1000 and incubated for 1 h at room temperature. The blot was incubated in an enhanced chemiluminescence kit and exposed to photographic film. The band intensities were measured by computer analysis using Quantitation software (Bio-Rad).
Transfection small interfering RNA
RASMCs (1 × 10 5 ) were seeded in 60-mm plates and incubated in antibiotic-free DMEM containing 10% FBS at 37°C. After 12 h, the medium was replaced with fresh antibiotics and FBS-free DMEM. The cells were then added and incubated with the small interfering RNA (siRNA) or nonsilencing control siRNA to a final concentration of 100 or 300 pM siRNA using transfection reagent (Welfect-Q TM Gold; Welgene, Daegu, Korea). After transfection for 48 h, the cells were harvested with the extraction buffer. The relative expression of SHP-2 was determined by immunoblotting analysis using an anti-SHP-2 antibody. The siRNAs were designed to target the sequences of rat SHP-2 (5′-GACUCUACAGC AACAGGAA-3′, Accession Number: NM_011202). The RNA of 19 nucleotides followed by TT were designed, synthesized chemically, purified, and annealed. Nonsilencing siRNA (5′-CCUACGCCACCAAUUUC GU-3′) was provided by Bioneer (Daejon, Korea).
Phosphatase activity assay
Phosphatase activity was measured using a malachite green SHP-2 activity kit (Duoset IC ELISA, R&D Systems). Cells (1 × 10 6 ) were treated with PDGF-BB, H 2 O 2 , or inhibitors. Cell lysates were incubated with anti-SHP-2 antibody conjugated to agarose immunoprecipitation beads that bind both active and inactive SHP-2. After washing away unbound material, a synthetic phosphopeptide substrate (DADEY PO3 LIPQQG) was added that is dephosphorylated by active SHP-2 to generate free phosphate and unphosphorylated peptides. The beads were pelleted by centrifugation (12,000 × g, 4°C, 5 min) and the supernatant was transferred to a microplate. The amount of free phosphate in the supernatant was determined by a sensitive dye-binding assay using malachite green and molybdic acid. The SHP-2 activity was determined from the rate of phosphate release.
Boyden chamber assay
Cell migration assays were performed in a 48-well microchemotaxis Boyden chamber (Neuroprobe, Adderbury, UK). Polycarbonate membranes with 8-μm pores were coated with 0.1 mg/ml of type I collagen from rat tail tendon and then dried for more than 1 h. RASMCs were harvested using trypsin-EDTA and resuspended in DMEM containing 0.1% BSA. Stimulators and test inhibitors were loaded in the bottom chamber and the membrane was laid over the cells. The chamber was incubated at 37°C for 70 min, and the membrane was fixed and stained using Diff-Quik (Sysmex Corp, Kobe). All samples used in the experiments contained 0.1% DMSO; the presence of DMSO did not affect RASMC migration. The number of cells migrating through the membrane was determined by counting 4 randomly chosen regions of each well under a microscope (×400).
Measurement of intracellular ROS generation
O 2 -production was measured using lucigenin-enhanced chemiluminescence. After various treatments, RASMCs (3 × 10 5 ) were lysed with Tris-based buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mM Na 3 VO 4 , 5 mM NaF, 1% Triton X-100, and 10% glycerol, pH 7.2). The supernatant was treated with 10 μM lucigenin and 500 μM NADPH. After treatment for 5 min, the chemiluminescence was measured repeatedly at 2-min intervals over 20 min using a luminometer (Victor 3; PerkinElmer, Boston, MA, USA). A single value was determined by averaging 5 readings at 20 min. The values were normalized to the total protein content. Intracellular H 2 O 2 accumulation in RASMCs was measured by using the green fluorescence probe 6-carboxy-2′,7′-dichlorofluoroscein diacetate (DCF-DA; Molecular Probes, Eugene, OR, USA). RASMCs (1 × 10 6 ) were treated for 10 min with or without PDGF-BB in a 24-well tissue culture plate. The cells were stained with 3 μM DCF-DA at 37°C for 15 min, which allows the rapid oxidization of DCF-DA to the highly fluorescent DCF in the presence of intracellular H 2 O 2 . The immunostained cells were observed with a confocal microscope (Olympus, Melville, NY, USA).
Balloon injury model
SD rats (350 -400 g) were anesthetized using a mixture of ketamine (80 mg/kg) and xylazine (12 mg/kg), and the left common and external carotid arteries were exposed and isolated. A 2F Fogarty catheter (Edwards Lifesciences, Irvine, CA, USA) was introduced into the common carotid artery through an arteriotomy in the external carotid artery and inflated to 1.0 -1.5 atmospheres. A 10-mm injury was induced by withdrawing the catheter 4 times. The external carotid artery was then tied, and the blood flow was restored. After the ballooninjury of the carotid artery, NSC-87877 (10 mg/kg per day) dissolved in distilled water was orally administered for 14 days. The control rats were also treated with a similar volume of distilled water (2 ml/kg per day). Animals were euthanized after 2 weeks and both side carotid arteries were dissected.
Immunohistochemistry
The arteries were washed in ice-cold PBS and fixed in 2% formalin. Segments from each half were embedded in paraffin and cross-sectioned. Sections were cleared with xylene, hydrated with ethanol, and incubated with Hematoxylin and Eosin (H&E) staining buffer or overnight at 4°C with primary antibodies at a 1:100 dilution. The incubated sections were treated with biotinylated pan-specific antibody (Vector Laboratories, Burlingame, CA, USA) for 1 h and incubated in ABC solution (Elite ABC kit, Vector Laboratories) prepared according to the manufacturer's directions. After 1-h incubation, the sections were stained with diaminobenzidine (DAB) reagent kit (Vector Laboratories) and with methyl green counterstain and then observed with a BX51 light microscope (Olympus, Tokyo).
Data analysis
Data are expressed as the mean ± S.E.M. The data were analyzed using Student's t-tests for comparisons between pairs of groups and by ANOVA for multiple comparisons. P values less than 0.05 were considered significant.
Results

PDGF-BB-stimulated SHP-2 phosphorylation in RASMCs
We measured the level of SHP-2 phosphorylation in RASMCs stimulated with PDGF-BB. Treatment with PDGF-BB (10 ng/ml) increased SHP-2 phosphorylation in a time-dependent manner (10 s to 30 min) and this response was maximal at 10 min (n = 4, Fig. 1A ). PDGF-BB (1 -20 ng/ml) dose-dependently increased the level of SHP-2 phosphorylation in RASMCs (n = 4, Fig. 1B ). , and with PDGF-BB (10 ng/ml) for 10 min after the pretreatment with NSC-87877 (30 μM) for 120 min (C). The cell lysates were then immunoblotted with anti-SHP-2, anti-phospho-SHP-2, anti-β-actin antibodies. Lower panels show statistical results obtained from each upper panel. The ratio of phospho-to nonphospho-SHP-2 in the basal state is deemed as 100% (n = 4). *P < 0.05. p-SHP-2, phosphorylated SHP-2. D -F: Activity of SHP-2 in response to PDGF-BB and an SHP-2 inhibitor under each experimental condition of panels A , B, and C. Phosphatase activity of lysates was assayed by measuring the formation of free phosphate using a malachite green assay as described in the Methods section (n = 6). *P < 0.05. NSC-87877, an inhibitor of SHP-2, at 30 μM attenuated the SHP-2 phosphorylation induced by 10 ng/ml PDGF-BB (117.4 ± 17.2% vs. 219.8 ± 13.5% of the control, n = 4; Fig. 1C ). Total expression levels of SHP-2 and β-actin, determined using anti-nonphosphorylated SHP-2 and anti-β-actin antibodies, respectively, were unchanged during PDGF-BB or NSC-87877 treatments (n = 4, Fig.  1 ). To clarify the relationship between phosphorylation and phosphatase activity of SHP-2, the SHP-2 activity was measured using a malachite green assay. Treatment of RASMCs with PDGF-BB (10 ng/ml) increased the release of phosphate and this response was maximal at 30 min (n = 4, Fig. 1D ). PDGF-BB (1 -20 ng/ml) dosedependently increased the SHP-2 activity in RASMCs (n = 4, Fig. 1E ). Treatment of cells with 30 μM of NSC-87877 attenuated the SHP-2 activity induced by 10 ng/ ml PDGF-BB (7.9 ± 0.1 μM vs. 10.9 ± 0.2 μM, n = 4; Fig. 1F ).
SHP-2 inhibition of PDGF-BB-stimulated VSMC migration
To clarify the role of SHP-2 in VSMC migration, we examined the effects of SHP-2 knockdown and inhibitors on PDGF-BB-induced migration in RASMCs. PDGF-BB (10 ng/ml) increased RASMC migration and this was inhibited by 30 μM NSC-87877 (n = 9, Fig. 2A ). As shown in Fig. 2B , RASMCs with the SHP-2 mRNA expression blocked using silencing siRNA showed a decreased expression of SHP-2. The relative SHP-2 expression level was 64.9 ± 8.5% for 100 pM of SHP-2-siRNA (n = 4) and 61.2 ± 7.6% for 300 pM (n = 4) compared with the expression values in cells transfected with 300 pM of nonsilencing RNA. The migration stimulated by PDGF-BB (10 ng/ml) was attenuated in cells transfected with 300 pM of SHP-2-siRNA (n = 8). In contrast, migration was not inhibited in cells transfected with nonsilencing siRNA and this was similar to the response in the nontransfected control.
SHP-2 inhibition on PDGF-BB-stimulated kinase activity
Our previous data showed that PDGF-BB increased Syk and p38 MAPK activation in VSMCs and that this was involved in VSMC migration (1) . Therefore, we measured the phosphorylation level of Syk/p38 MAPK in response to PDGF-BB in RASMCs treated with an SHP-2 inhibitor and siRNA. The level of p38 MAPK phosphorylation stimulated by 10 ng/ml of PDGF-BB for 10 min was significantly attenuated in cells treated with 30 μM of NSC-87877 (97.5 ± 4.9% vs. 271.3 ± 18.7% in the nontreated control, n = 4; Fig. 3A) . Similarly, inhibition of p38 MAPK phosphorylation was obtained in SHP-2 knockdown cells (162.7 ± 3.5% vs. 301.9 ± 5.0% in the nontransfected control, n = 4; Fig. 3B ). In contrast, the transfection of nonsilencing siRNA did not alter the phosphorylation levels of p38 MAPK in response to PDGF-BB and this response was similar to those in the nontransfected control cells. PDGF-BB had no effects on the total expression of p38 MAPK or β-actin (n = 4). The phosphorylation of Syk by 10 ng/ml of PDGF-BB (10 ng/ml) for 10 min in SHP-2 knockdown cells was inhibited to 226.0 ± 5.6% (n = 4) compared with the nonsilencing control (329.9 ± 3.3%, n = 4; Fig. 3C ). In the quiescent state, Syk phosphorylation was not changed by transfection with SHP-2-siRNA. The cells were preincubated with or without NSC-87877 (30 μM) for 120 min, and then stimulated with 10 ng/ml PDGF-BB for 70 min (n = 9). B: Alteration of PDGF-BB-stimulated migration in SHP-2-siRNA-transfected RASMC. Cells were transfected with 300 pM of nonsilencing siRNA, 100 or 300 pM of SHP-2-siRNA. SHP-2 expression was confirmed by immunoblotting using an anti-SHP-2 antibody (n = 4, upper panel) and the effect of SHP-2-siRNA transfection (300 pM) on PDGF-BB (10 ng/ml)-induced migration was examined in RASMC (lower panel, n = 8). Cell migration was measured in a Boyden chamber as described in the Methods section. The nonstimulated basal levels are expressed as 100%. *P < 0.05. Con, control; Non, nonsilencing siRNA; SI, SHP-2-siRNA. SHP-2 Participates in Neointima Formation
The relationship between ROS and PDGF-BB-induced responses in RASMCs
PDGF-BB induces phosphorylation of tyrosine in a variety of signaling proteins via the intracellular production of ROS (7, 26) . To elucidate whether the PDGF-BB-induced migration in RASMCs is mediated by ROS, we examined the effects of PDGF-BB on the production of ROS and the effects of ROS inhibitors on the PDGF-BB-induced migration in RASMCs. PDGF-BB (10 ng/ ml) increased the O 2 − level in RASMCs to 336.0 ± 30.7% of the value in the nonstimulated control (n = 7, Fig. 4A ). PDGF-BB markedly increased the level of DCF fluorescence in RASMCs compared with no treatment with PDGF-BB (523 ± 93.5% of control, n = 4; Fig. 4B ). The NOX inhibitor DPI (3 μM) inhibited the migration stimulated by 10 ng/ml of PDGF-BB in RASMCs (114.9 ± 7.1% vs. 241.0 ± 19.4% in the control, n = 8; Fig. 4C ). Tempol (3 mM), a free radical scavenger, and tiron (3 mM), an O 2 − scavenger, inhibited migration induced by PDGF-BB (10 ng/ml) to 141.2 ± 9.2% and 103.0 ± 7.5% of the nonstimulated control values, respectively (n = 8; Fig. 4C ). PDGF-BB (10 ng/ml) also induced SHP-2 phosphorylation in RASMCs (310.5 ± 25.9% of the nonstimulated control value). SHP-2 phosphorylation in response to PDGF-BB was inhibited by treatment with 3 μM DPI (174.9 ± 27.5%, n = 4), 3 mM tempol (145.1 ± 16.7%, n = 4), or 3 mM tiron (163.0 ± 12.1%, n = 4) (Fig. 4: D and E) . DPI, tempol, and tiron slightly inhibited the levels of migration and SHP-2 phosphorylation in non-stimulated cells (data not shown).
H 2 O 2 -induced migration and SHP-2 phosphorylation in RASMCs
Next, we confirmed the role of ROS in SHP-2-mediated RASMC migration. H 2 O 2 (10 -300 μM) dosedependently increased the migration of RASMCs, which reached a maximum at 100 μM and then decreased by 300 μM H 2 O 2 (n = 8, Fig. 5A ). We next examined the effects of H 2 O 2 on SHP-2 activation in RASMCs. H 2 O 2 (100 μM) elevated SHP-2 phosphorylation in a time-dependent manner (n = 4). The phosphorylation was maximal at 30 s and then decreased gradually from 60 to 300 s (Fig. 5B) . H 2 O 2 (1 -300 μM, 30 s) dose-dependently increased SHP-2 phosphorylation, reaching a maximal response at 100 μM (n = 4, Fig. 5C ). PDGF-BB did not alter the total expression of SHP-2 or β-actin (n = 4). 
Role of H 2 O 2 in the phosphorylation of Syk and p38 MAPK in RASMC
To determine whether H 2 O 2 increases the signal transduction activities that participate in the SHP-2-mediated PDGF responses, we measured the phosphorylation of Syk and p38 MAPK in response to H 2 O 2 . RASMCs treated with vehicle or 100 μM H 2 O 2 for 30 s were immunoprecipitated with an anti-Syk antibody and then subjected to immunoblot analysis. As shown in Fig. 5D , H 2 O 2 increased the phosphorylation of Syk in the cells without altering Syk expression (n = 4). Treatment of cells with 100 μM H 2 O 2 for 30 s increased the phosphorylation of p38 MAPK (n = 4, Fig. 5E ).
SHP-2 inhibition on vascular neointima formation and the expression and phosphorylation of SHP-2 in the formed neointima
We next tested the function of SHP-2 on the formation of neointima in rat carotid arteries using a balloon injury model of vascular neointima formation. The neointima area at 14 days after injury was significantly increased compared with sham-operated control artery. Balloon injury-induced neointima formation was significantly attenuated by an oral treatment with 10 mg/kg per day of NSC-87877 for 14 days after injury (n = 9 in each group, Fig. 6A) .
To confirm the expression pattern of SHP-2 on the neointima of carotid arteries, we used a model of neointimal formation in balloon-injured vessel. The neointimal area and the medial smooth muscle layer showed SHP-2 expression. Phosphorylation of SHP-2 was also observed on the neointimal layer. SHP-2 expression and phosphorylation were increased in the neointimal area compared with the medial smooth muscle layer (n = 4 in each group, Fig. 6B ).
Discussion
In this study, we found that PDGF-BB increased the activity of SHP-2 and migration in RASMCs and that − production in PDGF-BB (10 ng/ml)-stimulated cells was measured using a lucigenin-enhanced chemiluminescence assay as described in Materials and Methods (n = 7, A). Intracellular H2O2 generation in response to PDGF-BB (10 ng/ml) was measured using the green fluorescence probe DCF-DA (n = 4, B). White colors, H2O2-positive cells. C: Effects of ROS inhibition on PDGF-BB-induced RASMC migration. The cells were preincubated with DPI (3 μM), tempol (Temp; 3 mM), or tiron (3 mM) for 120 min, and then they were stimulated with 10 ng/ml PDGF-BB for 70 min. Migration in the quiescent state is expressed as 100% (n = 8). D: Effects of ROS inhibition on the phosphorylation of SHP-2 in response to PDGF-BB in RASMC. Cells were treated with or without DPI (3 μM), tempol (3 mM), or tiron (3 mM) for 60 min, and then they were stimulated with PDGF-BB (10 ng/ml) for 10 min. E: The statistical data obtained from panel D. The ratio of phospho/nonphospho-SHP-2 in the basal state is presented as 100% (n = 4). *P < 0.05. p-SHP-2, phosphorylated SHP-2. these responses were suppressed by the treatment of the SHP-2 inhibitor NSC-87877 and in SHP-2 knockeddown cells. This result implies that SHP-2 could be involved in VSMC migration in response to PDGF. Although SHP-2 is reported to respond to PDGF stimulation and participates in motility in a variety of cells (14, 23) , it is unknown whether SHP-2 activity contributes to the regulation of VSMC migration. In the present study, we provide the first direct evidence for the contribution of SHP-2 activity to the regulation of VSMC migration.
The proliferation and migration of medial smooth muscle cells is an essential process for vascular remodeling and neointima hyperplasia in atherosclerosis (1, 8) . Although previous reports showed that the expression of SHP-2 increased in the neointima after balloon injury (25, 26) , its role in neointima formation is not clarified. We also confirmed here that SHP-2 expression can be found in both the medial and neointimal layers after a balloon injury of the carotid artery. Furthermore, oral administration of NSC-87877 significantly inhibited the formation of neointima in the injured rat carotid artery. These results suggest strongly that the SHP-2 activity induced by extracellular stimuli participates in the formation of neointima in atherosclerosis through its contribution to VSMC migration. In addition, we suggest that the inhibition of SHP-2 using NSC-87877 or its derivatives presents a new useful therapeutic strategy to prevent diseases associated with vascular remodeling including neointima hyperplasia and restenosis. SHP-2 participates in several signaling cascades associated with the MAPK pathway and is required for full activation of the pathway (21, 27) . The inactivation of SHP-2 prevents MAPK activation in response to various stimuli (24) . In our study, the PDGF-BB-increased phosphorylation of Syk and p38 MAPK was inhibited by NSC-87877 and in VSMCs transfected with SHP-2-siRNA, indicating that SHP-2 acts upstream of Syk and p38 MAPK. Other previous reports demonstrated that ROS were associated with the migration induced by PDGF-BB and activate MAPK in a variety of cells (1, 9) . Moreover, VSMC migration increased by extracellular stimuli was attenuated by the inhibition of NOX (20) . Taken together, these data suggest that SHP-2-induced VSMC migration and neointima formation may be mediated by the stimulation of Syk/p38 MAPK via elevation of ROS levels.
ROS can oxidize PTPs and consequently reduce the phosphatase activity and increased phosphorylation of its substrates (5). These forms are termed 'negative PTPs' in terms of responses to extracellular stimuli and receptor tyrosine kinases. In contrast, the activity of 'positive PTPs' is increased by extracellular stimuli (19, 20) . In this study, SHP-2 activity assayed using malachite green showed that PDGF-BB increased the activity of SHP-2, which showed a similar pattern to its phosphorylation. Previously, both phosphorylation and the activity of SHP-2 were shown to be elevated similarly when VSMCs were stimulated by angiotensin II (28, 29) . It has been reported that H 2 O 2 increases the phosphorylation of SHP-2 as well as its activity (30) . Previously, it was suggested that phosphorylation of Y542 and Y580 in the C-terminal tail of SHP-2 regulates its activity, and phosphorylated SHP-2 can be bound to the N-SH2 and C-SH2 domains to stimulate SHP-2 activity (27, 31) . These results implied that the activity of SHP-2 can be replaced by its phosphorylation at least in part and that SHP-2 acts as a positive PTP. Furthermore, SHP-2 could act upstream of SFK to promote MAPK activation in response to growth factor stimulation through the dephosphorylation of some adaptor proteins including Vav1, Gab2, Stat3, and Cbp/PAG (24, 27) . It is known that Src is stabilized in an inactive confirmation when it is phosphorylated at Y529 by Csk (32) . The dephosphorylated form of Csk releases this binding to SFK, which increases the activity of Src and SFK (14) . These results suggest that an active PTP, such as SHP-2, might transit its signal to Src and SFK through the increased dephosphorylation of Csk, and reduce the inhibition of binding between Csk and SFK (Fig. 6C) .
Moreover, ROS can act as an important molecule in promoting signals relative to a variety of cellular functions including apoptosis and proliferation (33 are similar to the responses to PDGF-BB in RASMCs, implying that PDGF-produced H 2 O 2 participates in VSMC migration via the Syk signal, probably followed by p38 MAPK activity. We also showed that PDGF-induced SHP-2 phosphorylation is inhibited markedly by treatment with a NOX inhibitor or ROS scavengers and that H 2 O 2 increases the phosphorylation of SHP-2 in RASMCs, suggesting that H 2 O 2 acts as an upstream molecule of SHP-2 in response to PDGF in RASMC. Therefore, these data suggest that the phosphorylation of SHP-2 is involved in the cell responses to PDGF, especially migration, and that migration is mediated by the increased H 2 O 2 generation followed by the stimulation of the Syk and p38 MAPK pathway in RASMCs.
In summary, we demonstrated that PDGF-BB increased migration and SHP-2 activation and phosphorylation and that these responses were attenuated by the inhibition of SHP-2 in RASMCs. PDGF-BB also induced Syk/p38 MAPK phosphorylation, which was inhibited by SHP-2 inhibition. Moreover, PDGF-BB increased ROS production, and PDGF-BB-induced migration and SHP-2 phosphorylation were suppressed by the treatment of ROS inhibitors. H 2 O 2 increased RASMC migration and the phosphorylations of SHP-2, Syk, and p38 MAPK. Oral administration of an SHP-2 inhibitor decreased the balloon injury-induced neointima formation in the carotid artery. Our data suggest that SHP-2, which could be controlled by H 2 O 2 , is positively involved in the regulation of migration in VSMCs induced by PDGF-BB and that this response is induced via the Syk and p38 MAPK pathway. Therefore, these events may contribute to the neointima formation in vascular remodeling involved in atherosclerosis.
